Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT04452214
Title A Study of the Safety and Tolerance of CAN04 in Combination With Pembrolizumab in Subjects With Solid Tumors
Recruitment Recruiting
Gender both
Phase Phase I
Variant Requirements No
Sponsors Cantargia AB
Indications

transitional cell carcinoma

head and neck squamous cell carcinoma

melanoma

lung non-small cell carcinoma

Therapies

Nidanilimab + Pembrolizumab

Age Groups: senior | adult
Covered Countries USA


No variant requirements are available.